Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISORDIL vs CIRCANOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.
CIRCANOL (flupentixol) is a thioxanthene derivative that acts as a dopamine D1/D2 receptor antagonist, with higher affinity for D2 receptors, and also exhibits antagonism at serotonin 5-HT2 receptors. It modulates neurotransmission in the mesolimbic and mesocortical pathways, reducing positive symptoms of schizophrenia and exerting antidepressant effects at low doses via presynaptic dopamine receptor blockade.
Angina pectoris (prophylaxis and acute treatment),Heart failure (off-label: adjunctive treatment in acute myocardial infarction)
Schizophrenia (maintenance therapy),Other psychotic disorders,Depression (low-dose augmentation in resistant cases)
Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.
4 mg orally once daily.
Terminal half-life: 1–4 hours (isosorbide dinitrate); clinical context: short duration requires frequent dosing or sustained-release formulations.
Terminal elimination half-life is 14-18 hours in patients with normal renal function; prolonged in renal impairment.
Primarily hepatic via glutathione-organic nitrate reductase; also undergoes denitration to active metabolites (isosorbide-2-mononitrate and isosorbide-5-mononitrate).
Primarily hepatic via CYP2D6 and CYP3A4, forming metabolites including N-dealkylated and sulfoxide derivatives; undergoes extensive first-pass metabolism.
Renal: 80% as inactive metabolites; biliary/fecal: 20% as conjugates.
Primarily renal (70-90% unchanged) with minor biliary/fecal (5-15%)
~28% bound to albumin.
40-50% bound to albumin and α1-acid glycoprotein
2–4 L/kg, indicating extensive tissue distribution.
1.2-1.8 L/kg; indicates extensive extravascular distribution, possibly due to tissue binding.
Sublingual: ~40–60% (first-pass bypassed); oral: <30% due to extensive first-pass hepatic metabolism.
Oral: 60-75% due to first-pass metabolism
No specific GFR-based dose adjustments are recommended; however, caution is advised in severe renal impairment due to potential accumulation of metabolites.
No dose adjustment required for GFR ≥30 m L/min; not recommended for use if GFR <30 m L/min.
In Child-Pugh class A: no adjustment. Child-Pugh class B and C: reduce dose by 50% and monitor for hypotension.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 2 mg once daily; Child-Pugh C: not recommended.
Isosorbide dinitrate: not recommended for use in children due to lack of safety and efficacy data; no established pediatric dosing guidelines.
Not approved for pediatric use; safety and efficacy not established.
Elderly patients may have increased sensitivity to hypotension. Initiate with lowest doses (e.g., 5 mg orally twice daily) and titrate slowly. Monitor blood pressure and orthostatic changes.
Start at 2 mg orally once daily; increase to 4 mg as tolerated based on response and renal function.
Do not use in patients with erectile dysfunction medications (PDE-5 inhibitors) due to risk of severe hypotension.
None
Hypotension (especially with volume depletion or alcohol),Tolerance with prolonged use (intermittent dosing recommended),Exacerbation of angina upon abrupt withdrawal,Use cautiously in hypertrophic cardiomyopathy
Extrapyramidal symptoms (acute dystonia, akathisia, parkinsonism); tardive dyskinesia with long-term use; neuroleptic malignant syndrome; QT interval prolongation; increased mortality in elderly patients with dementia-related psychosis; seizures; hepatic impairment; hematologic effects (leukopenia, neutropenia); anticholinergic effects; orthostatic hypotension; hyperprolactinemia.
Hypersensitivity to nitrates,Concurrent use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil),Severe anemia,Increased intracranial pressure (head trauma, cerebral hemorrhage),Acute circulatory failure (shock, vascular collapse)
Comatose states; CNS depression; severe liver disease; blood dyscrasias; pheochromocytoma; known hypersensitivity to flupentixol or other thioxanthenes; concurrent use with dopamine agonists (except in Parkinson's disease psychosis).
Avoid excessive alcohol consumption. No specific food interactions; however, high-fat meals may delay absorption of oral formulations. Maintain consistent dietary habits to minimize variations in drug effects.
Avoid grapefruit and grapefruit juice as they may increase drug levels and risk of side effects. No other significant food interactions. Maintain adequate hydration to prevent hypotension.
Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. It should be used during pregnancy only if clearly needed. Potential fetal risks include hypotension and reduced uteroplacental perfusion, particularly in the first trimester. Second and third trimester risks are theoretical due to maternal hemodynamic changes. Avoid use near term due to risk of neonatal methemoglobinemia. FDA pregnancy category C.
First trimester: Evidence of human fetal harm based on retrospective studies showing increased risk of congenital anomalies (cardiac defects, neural tube defects) with first-trimester exposure. Second and third trimesters: Risk of fetal hypotension, neonatal respiratory depression, and withdrawal syndrome with chronic use; avoid near term due to risk of premature ductus arteriosus closure.
Excretion in human milk is unknown. Due to potential for serious adverse reactions in nursing infants (e.g., methemoglobinemia), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio not reported.
Small amounts excreted into breast milk (M/P ratio approximately 0.3-0.5). Considered compatible with breastfeeding due to limited oral bioavailability in infants; however, monitor infant for sedation or poor feeding.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance; however, no specific dose adjustments are established. Use lowest effective dose with careful titration to avoid hypotension. Initiate with 5-10 mg sublingual for acute episodes; for prophylaxis, 10-40 mg orally every 6 hours. Monitor for excessive hypotension.
Increased volume of distribution and renal clearance in pregnancy may necessitate higher doses to maintain therapeutic effect; however, due to fetal risks, use lowest effective dose for shortest duration. No standard dose adjustment; individualize based on clinical response and tolerability.
Isordil (isosorbide dinitrate) is a nitrate vasodilator used for angina prophylaxis. Sublingual formulation provides rapid onset for acute attacks; oral sustained-release is for chronic prophylaxis. Tolerance develops with continuous exposure; use a daily nitrate-free interval of 10-12 hours. Avoid use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Monitor for headache, hypotension, and reflex tachycardia.
Circanol (ergoloid mesylates) is a vasodilator used primarily for age-related cognitive decline. Monitor for orthostatic hypotension, especially in elderly patients. Onset of benefit may take several weeks; discontinue if no response after 3-6 months. Avoid use in patients with a history of psychosis or severe hypotension. Can be used as adjunctive therapy for dementia but not a first-line agent.
Take sublingual isordil at the first sign of an angina attack; sit down before using to avoid dizziness.,For chronic prophylaxis, take as prescribed; do not skip doses to maintain the nitrate-free interval.,Avoid alcohol as it can increase the risk of hypotension and dizziness.,Report any severe headaches, worsening chest pain, or fainting to your healthcare provider immediately.,Never take erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on isordil.
Take Circanol exactly as prescribed; do not stop abruptly.,Rise slowly from sitting or lying to prevent dizziness or falls.,Report any fainting, rapid heart rate, or severe headache immediately.,Avoid alcohol as it may worsen side effects like dizziness and low blood pressure.,Improvement in symptoms may take 4-12 weeks; continue medication as directed even if no immediate benefit.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISORDIL vs CIRCANOL, answered by our medical review team.
ISORDIL is a Nitrate Vasodilator that works by Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.. CIRCANOL is a Vasodilator (Peripheral) that works by CIRCANOL (flupentixol) is a thioxanthene derivative that acts as a dopamine D1/D2 receptor antagonist, with higher affinity for D2 receptors, and also exhibits antagonism at serotonin 5-HT2 receptors. It modulates neurotransmission in the mesolimbic and mesocortical pathways, reducing positive symptoms of schizophrenia and exerting antidepressant effects at low doses via presynaptic dopamine receptor blockade.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISORDIL and CIRCANOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISORDIL is: Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.. The standard adult dose of CIRCANOL is: 4 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISORDIL and CIRCANOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISORDIL is classified as Category C. Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. CIRCANOL is classified as Category C. First trimester: Evidence of human fetal harm based on retrospective studies showing increased risk of congenital anomalies (cardiac defects, neural tube defects) with first-trimes. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.